Emerging Safety Profile of Vedolizumab: A novel, selective Integrin Inhibitor for the treatment of IBD
Brian G. Feagan(Western University), Irving H. Fox(Takeda (United States)), Catherine Milch(Millennium Engineering and Integration (United States)), A. Parikh(Takeda (United States)), Timothy Leach(Takeda (United States))
Cited by 6
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k